MicroRNA 182 (miR-182) (miR-182)

MicroRNA 182 (miR-182) is a small non-coding RNA molecule that plays a pivotal role in the post-transcriptional regulation of gene expression by binding to the 3' untranslated regions (UTRs) of target messenger RNAs [1]. It is a member of the polycistronic miR-183/96/182 cluster, which is highly conserved and critical for the development and physiological function of sensory organs, particularly the retina and the inner ear [2][3]. In the context of human disease, miR-182 is frequently dysregulated and is most notably recognized for its role in oncology, where it often acts as an oncomir by promoting cell survival, proliferation, and metastasis [4]. It achieves these effects by silencing key tumor suppressors and DNA repair genes, such as FOXO1 and BRCA1, thereby contributing to the progression of breast cancer, melanoma, and prostate cancer [5][6]. Because of its significant impact on cancer pathways and its presence in circulation, miR-182 is being investigated both as a diagnostic biomarker and as a therapeutic target [7]. Therapeutic approaches involve the use of antisense oligonucleotides, known as antagomirs, to inhibit its activity in overexpressing tumors, or miRNA mimics to restore its function in cases where it acts as a tumor suppressor [8]. Additionally, its role in DNA damage response suggests that targeting miR-182 could sensitize cancer cells to existing treatments like PARP inhibitors [6]. Despite its therapeutic potential, challenges remain regarding the precise delivery of miRNA-based drugs and the mitigation of off-target effects in non-cancerous tissues [7].

Other names

hsa-miR-182miR-182-5pMIR182MicroRNA 182-5p

Post-transcriptional gene silencing through mRNA degradation or translational inhibition by binding to the 3' untranslated region (UTR) of target mRNAs.